Abstract
Spinal cord injury (SCI) is a devastating, life-altering, neurological event that affects ∼300,000 individuals in the United States. Currently, there are no effective treatments to reverse the neurological impairments caused by the lesion. Until a cure is available, there is an urgent need for strategies that can either spare injured neurons or promote neuroplasticity and functional recovery. Genetic links to outcomes after SCI may provide insights into the pathological mechanisms, and possible new avenues for drug development. In the present review, we discuss the current knowledge linking apolipoprotein E genotypes with better or worse functional outcomes after an SCI, and the possible molecular mechanisms that may contribute to this association.
Original language | English (US) |
---|---|
Pages (from-to) | 3317-3322 |
Number of pages | 6 |
Journal | Journal of neurotrauma |
Volume | 36 |
Issue number | 24 |
DOIs | |
State | Published - Dec 15 2019 |
Externally published | Yes |
Bibliographical note
Funding Information:This work was supported by the New York State Department of Health, Wadsworth Center, Innovative, Developmental or Exploratory Activities (IDEA) in Spinal Cord (NYS Spinal Cord Injury Research Board [SCIRB] Grant# DOH01-PART2-2017-00035 to C.P.C. and D.C.), and the Department of Veterans Affairs Rehabilitation and Development Service Grant B-2020-C.
Publisher Copyright:
© Copyright 2019, Mary Ann Liebert, Inc., publishers 2019.
Keywords
- SCI neuropathology
- apolipoprotein E
- functional recovery after SCI